Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SoftMedX Healthcare's EBITDA for the
six
months ended in Jun. 2026 was HK$5.88 Mil. SoftMedX Healthcare's Revenue for the
six
months ended in Jun. 2026 was HK$34.08 Mil. Therefore, SoftMedX Healthcare's EBITDA margin for the quarter that ended in Jun. 2026 was 17.25%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SoftMedX Healthcare EBITDA Margin % Related Terms
SoftMedX Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SoftMedX Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00648 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, SoftMedX Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SoftMedX Healthcare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SoftMedX Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SoftMedX Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SoftMedX Healthcare (HKSE:00648) has a EBITDA Margin % of 17.25% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SoftMedX Healthcare and its competitors. According to the industry distribution chart, SoftMedX Healthcare ranks #214 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 32.1%.
Is SoftMedX Healthcare's EBITDA Margin % too high?
SoftMedX Healthcare's current EBITDA Margin % is 17.25%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. SoftMedX Healthcare's value of 17.25% is 68.6% above this industry median. Based on the distribution chart, SoftMedX Healthcare ranks #214 out of 667 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, SoftMedX Healthcare has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SoftMedX Healthcare's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, SoftMedX Healthcare ranks #214 out of 667 companies for EBITDA Margin %. This puts SoftMedX Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 10.23. SoftMedX Healthcare's value of 17.25% is 68.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SoftMedX Healthcare's current EBITDA Margin % of 17.25% is 68.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SoftMedX Healthcare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftMedX Healthcare's current EBITDA Margin % is 17.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftMedX Healthcare stock overvalued right now?
Based on GuruFocus' analysis, SoftMedX Healthcare (HKSE:00648) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.52, compared to a current price of HK$0.57 — trading 77.4% below its estimated fair value. The current EBITDA Margin % is 17.25% and 68.6% above the Healthcare Providers & Services industry median of 10.23. SoftMedX Healthcare's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SoftMedX Healthcare (HKSE:00648), the current EBITDA Margin % is 17.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SoftMedX Healthcare (HKSE:00648) Overvalued in 2026?
Based on GuruFocus' analysis, SoftMedX Healthcare stock appears to be undervalued.
The current stock price of HK$0.57 is trading 77.4% below its estimated GF Value™ of HK$2.52.
GuruFocus considers SoftMedX Healthcare to be Possible Value Trap.
Key valuation signals for HKSE:00648:
EBITDA Margin %: 17.25%
GF Value™: HK$2.52 vs. price of HK$0.57 (77.4% below fair value)
Industry Position: 68.6% above the Healthcare Providers & Services median (#214 of 667)
No single metric tells the full story. See the HKSE:00648 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SoftMedX Healthcare Ltd is principally engaged in the distribution of medical and healthcare equipment and products. The Group has one reportable operating segment: medical and well-being business, for the Distribution of medical and healthcare equipment and products.
54GF Score
Get the complete analysis for HKSE:00648
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00648 has been successfully added to your 
